“X-linked Retinitis Pigmentosa Pipeline” report has been added to DelveInsight
DelveInsight’s, “X-linked Retinitis Pigmentosa – Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in X-linked Retinitis Pigmentosa pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Get a free sample copy here- https://www.delveinsight.com/sample-request/x-linked-retinitis-pigmentosa-pipeline-insight
X-linked Retinitis Pigmentosa Pipeline analysis across different stages of development (Phase III & Phase II), different emerging trends and comparative analysis of X-linked Retinitis Pigmentosa pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities
X-linked Retinitis Pigmentosa Overview
X-linked Retinitis Pigmentosa (XLRP) caused by mutations in the Retinitis Pigmentosa GTPase regulator (RPGR) gene is the most common form of recessive RP. The RPGR gene is located on the X-chromosome; this is why the disease affects men and women in a different way. XLRP affects boys and young men by initial symptoms, such as night blindness and lack of dark adaptation, within the first decade of life. In the second decade, patients usually have a reduced visual field and visual acuity, which later results in complete blindness by the third or fourth decade of life.
X-Linked Retinitis Pigmentosa Pipeline: Geography Covered
X-Linked Retinitis Pigmentosa Key Players
X-Linked Retinitis Pigmentosa Drugs
X-Linked Retinitis Pigmentosa Symptoms
XLRP affects boys and young men by initial symptoms, such as night blindness and lack of dark adaptation, within the first decade of life. In the second decade, patients usually have a reduced visual field and visual acuity, which later results in complete blindness by the third or fourth decade of life.
X-linked Retinitis Pigmentosa Pipeline Report
Female carriers may also be affected with a milder form of the disease with peripheral pigmentary changes in the retina. XLRP often results in total blindness, and there is no specific treatment for this condition. Mutations in the RPGR gene can be associated with a rod-cone or cone-rod dystrophy phenotype. It is initially identified with difficulties in scotopic visual function, where there is a predominant loss of rod photoreceptors. Also, there is peripheral vision deteriorates, resulting in visual field narrowing on perimetry findings. In some cases, patients also present early cone involvement and correspondingly impaired central visual acuity during early stages of the disease.
X-linked Retinitis Pigmentosa Pipeline Insights
X-linked Retinitis Pigmentosa (XLRP) is an inherited condition which causes progressive vision loss predominantly in males. The condition begins with night blindness and leads to total loss in vision.
Table of content
Introduction
What are the key questions answered?
X-Linked Retinitis Pigmentosa Research Methodology
The objective of updating DelveInsight coverage is to ensure that it represents the most up-to-date vision of the industry possible. The DelveInsight is a fully integrated solution for comprehensive intelligence on various pharmaceutical products, both in the market and in the pipeline, across the globe
About DelveInsight
DelveInsight is a Business Consultant company and serves as a Knowledge partner across the value chain of the Pharmaceutical Industry. With the use of proprietary databases and analytical models, DelveInsight provides cutting-edge market and pipeline analysis and API intelligence across all therapy areas to the Pharma and biotech sector, helping clients to quantify market events and evaluate their impact on the valuation of products, portfolios, and companies.
Contact us
Shruti Thakur
[email protected]
+91-9650213330
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/